POTENTIAL SOLUTIONS: The acceptance and utilization of biosimilars in IBD, and consequent improved access to early anti-TNF-α therapy, can be improved by continued education on the robustness of the biosimilar development process and the safety of transitioning between reference and biosimilar medicines [9]. Here, TNF is linked to inflammatory bowel disease.